Main Uses and Benefits of Зоэли (Zoely)

The primary therapeutic application of this medicine is relevant for easing symptoms that interfere with daily functioning, specifically the prevention of pregnancy. This is applied across domains where additional symptomatic support is needed for long-term reproductive planning.

The pill is commonly used to help with certain symptom clusters that interfere with daily functioning, primarily related to the menstrual cycle. Indications where the medication is considered relevant include supporting the patient during episodes of heightened discomfort from painful menstruation (dysmenorrhea), and helping address symptoms related to systemic imbalance like acne.

“The use of this medication may be relevant for easing symptoms that interfere with daily comfort in conditions involving episodic or fluctuating manifestations.”

Aiding Cycle Regularity and Comfort

This medication is commonly used to help with symptoms related to systemic imbalance, such as episodic or fluctuating manifestations that affect the bleeding pattern. This assists with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Supportive Management for Cyclic Symptoms
Primary Domain: Relevant in contexts marked by increased discomfort or tension related to fertility.
Symptom Support: Helps address symptom clusters that may become intense or disruptive, such as physical discomfort and symptoms that interfere with daily functioning.
Lifestyle Benefit: Supports general well-being during symptomatic phases.

Zoely is a combined hormonal contraceptive strictly contraindicated for use in populations with specific risk factors and clinical conditions, as defined in official regulatory documents.

Populations Who Must Not Use Zoely (Contraindications)

Use is prohibited if any of the following are present:

• Thromboembolism: Current or past venous thromboembolism (VTE), such as deep vein thrombosis (DVT) or pulmonary embolism (PE); or arterial thromboembolism (ATE), such as a heart attack, stroke, or severe risk factors like severe hypertension or diabetes mellitus with vascular damage.
• Known Predisposition: Known hereditary or acquired predisposition to VTE or ATE (e.g., Factor V Leiden, Protein C/S deficiency, or hyperhomocysteinaemia).
• Severe Organ Disease: Current or history of severe hepatic disease (until liver function values have returned to normal), benign or malignant liver tumours, or pancreatitis associated with severe hypertriglyceridaemia.
• Malignancy: Known or suspected sex steroid-influenced cancers (e.g., breast or genital organ cancer) or a history of meningioma.
• Other Conditions: Undiagnosed vaginal bleeding, known or suspected pregnancy, or hypersensitivity to the active substances or excipients.

Restricted or Non-Established Use

• Pregnancy and Lactation: The medicine is contraindicated during pregnancy and not recommended for use while breastfeeding.
• Adolescents: Safety and efficacy have not been established in post-menarcheal adolescents under 18 years of age. There is no relevant use in pre-menarcheal children.
• Postpartum: Starting use between day 21 and 28 postpartum requires careful consideration of the increased VTE risk in the puerperium.

Interactions with other medicines and products

Zoely's official regulatory profile identifies specific interaction patterns, primarily revolving around the drug's metabolism and its effect on certain co-administered substances.

Formal Contraindicated Combinations

Substance Category	Interaction Detail
Hepatitis C Antivirals	Co-administration is contraindicated with combination regimens containing ombitasvir/paritaprevir/ritonavir with or without dasabuvir due to the documented risk of liver enzyme (ALT) elevations.

Interactions Affecting Hormone Levels

Substance Group	Official Outcome (Mechanism)
Enzyme Inducers (e.g., Rifampicin, Carbamazepine, Phenytoin)	Reduced plasma concentrations of contraceptive hormones due to increased clearance via CYP3A4 enzyme induction, risking decreased effectiveness.
Enzyme Inhibitors (e.g., Ketoconazole)	Increased plasma concentrations of the contraceptive hormones due to CYP3A4 inhibition.
Antibiotics (e.g., Ampicillin, Tetracyclines)	Documented risk of reduced contraceptive effectiveness.
St John's Wort	Reduced contraceptive effectiveness due to enzyme induction.

Other Pharmacodynamic Interactions

Zoely's components can affect other drugs, most notably Lamotrigine, where co-administration results in reduced Lamotrigine plasma concentrations due to induced clearance (glucuronidation). Furthermore, the medication is not indicated in patients with severe hepatic disease due to the potential for impaired clearance and drug accumulation.

Central Suppression of Reproductive Hormones

The mechanism of action involves the combined delivery of two synthetic hormones, which primarily act on receptors within the hypothalamic-pituitary-ovarian (HPO) axis. This targeted signaling modulates the central neuroendocrine pathway by initiating negative feedback signals to the hypothalamus and pituitary gland. This cascade results in the suppression of the Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) surge, leading to the system-level physiological consequence of anovulation.

---

Modification of Peripheral Reproductive Tissues

The components also exert local influence on peripheral tissues. The Nomegestrol acetate component acts as a selective agonist on progesterone receptors (PR). This activity alters cellular signaling in the cervix and the endometrium, leading to two structural adjustments: thickening of the cervical mucus and changes to the uterine lining. These modifications alter the reproductive tract's local environment, reinforcing the overall mechanistic profile.

Official Administration Guidelines for Зоэли

The official administration of Zoely is based on a fixed daily schedule for continuous use. The medication is delivered exclusively by the oral route, with one tablet swallowed whole each day.

Instruction	Description
Route of administration:	Oral route only (tablet must be swallowed).
Dosing schedule:	One tablet taken daily for 28 consecutive days, utilizing a 24/4 regimen consisting of 24 white active tablets (2.5 mg nomegestrol acetate / 1.5 mg estradiol) followed by 4 yellow placebo tablets.
Timing in relation to meals (if applicable):	Taken without regard to meals, with some liquid as needed.

---

Procedural Structure and Administration Scope

The dosing structure requires strict adherence to the tablet sequence and timing. The tablets must be taken in the sequential order directed on the blister pack, and it is necessary to take the tablet at approximately the same time every day.

Instruction	Description
Age-group administration rules:	Postpartum/Second-trimester Abortion: Initiation is advised to start between Day 21 and Day 28 following delivery or a second-trimester abortion.
Special procedural conditions:	If vomiting or severe diarrhoea occurs within 3–4 hours of taking a white active tablet, the tablet is regarded as a missed dose, and the appropriate established guidance must be followed.

The usage protocol mandates that a new pack must be started immediately after finishing the previous pack, ensuring no break in daily tablet intake. Specific established protocols are followed when managing a missed active tablet, which vary based on the elapsed time and the week of the cycle.

Research Evidence for Зоэлі: Overview of Studies

Evidence Supporting the Primary Use: Pregnancy Prevention

The primary clinical evidence for which Зоэлі was studied for pregnancy prevention involved large, international randomized controlled trials (RCTs). Researchers measured contraceptive efficacy using the Pearl Index (a common measure for unintended pregnancy rates). Studies reported measurements of contraceptive efficacy that were in the range typically observed for combined oral contraceptives. The difference in efficacy between Зоэлі and the specific comparator product was not found to be statistically significant.

Longer-term data relies on extended prospective observational studies conducted after the medicine became available. These involved large user cohorts and provided additional context regarding sustained use over several years. However, the main RCTs provided intermediate-term follow-up (1 year), and the core trials compared the medicine to only one specific combined oral contraceptive, limiting broader conclusions.

Studies Examining Menstrual Cycle Control and Bleeding Patterns

Research has explored how the medicine affects the menstrual cycle by analyzing data from the main trials. Studies monitored the incidence and duration of both scheduled withdrawal bleeding and unscheduled (breakthrough) bleeding or spotting. Outcomes related to functional imbalance was observed in studies, specifically tracking the absence of withdrawal bleeding (amenorrhea).

Studies reported that the median duration of scheduled withdrawal bleeding was lower than the comparator pill used in the trials. The incidence of absence of scheduled withdrawal bleeding increased progressively over 12 months, affecting approximately one-third of women in certain trials. Uncertainty exists because the comparator pill used a different dosing regimen (21/7 versus 24/4), which influences bleeding profiles.

Evaluation of Supportive Outcomes: Menstrual Symptoms

The medicine was studied for outcomes related to physical discomfort and daily functioning. Secondary analyses of trial data and prospective studies examined changes in symptom severity scores, tracking domains such as pain/dysmenorrhea, fluid retention, and mood/affect. Research describes patterns where symptom rating scores related to the menstrual cycle were reported to change over 12 months of use in some prospective cohorts. Evidence in this area is limited as symptomatic relief was generally evaluated as a secondary outcome, and findings relied on subjective patient-reported outcomes describing perceived discomfort.

Key Studies & References

1. Combined oral contraception: nomegestrol/estradiol (Zoely) - NICE Evidence Summary (Review of RCTs for Efficacy and Bleeding)

Common questions about Зоэли (FAQ)

---

Q: Чем Зоэли отличается от других противозачаточных таблеток?

Official product information notes two key distinguishing features. Firstly, Zoely contains natural 17β-estradiol as its estrogen component, unlike most other combined pills which use synthetic ethinylestradiol. Secondly, it follows an extended active-tablet schedule of 24 days, followed by only 4 days of placebo tablets.

Q: Можно ли использовать Зоэли, если у меня есть проблемы с весом?

Regulatory documents indicate that obesity (defined as a Body Mass Index (BMI) over 30 kg/m^2) is a recognized risk factor for developing serious circulatory conditions, such as thrombosis, when using combined hormonal contraceptives. This risk factor is taken into account by healthcare providers.

Q: Правда ли, что Зоэли содержит натуральные гормоны?

The medicine contains a combination of hormones. The estrogen component, estradiol, is structurally identical to the natural estrogen produced by the body. However, the progestogen component, nomegestrol acetate, is a synthetic hormone.

Q: Как быстро начинает действовать Зоэли?

If the first active tablet is started on Day 1 of the menstrual cycle (the first day of bleeding), then contraceptive protection is generally considered established on that day, and no additional barrier method is necessary. If the pill is started on Days 2 to 5 of the cycle, a barrier contraceptive method is generally recommended until 7 continuous days of active tablets have been completed.

Q: Влияет ли прием Зоэли на настроение или эмоциональное состояние?

According to the drug's official adverse reaction data, depressed mood is classified as a Common side effect, meaning it may affect between 1% and 10% of users. Changes in mood are acknowledged in the product information.

Q: Безопасно ли принимать Зоэли длительное время?

The risk of Venous Thromboembolism (VTE) is officially noted as being highest during the first year of use or after restarting. The safety profile for long-term use is monitored through extended prospective observational studies conducted after the medicine became available to the public.

Q: Нужно ли использовать дополнительную защиту в первые дни приема Зоэли?

Yes, if the first active tablet is taken on Days 2 to 5 of the menstrual cycle, official guidelines recommend a barrier contraceptive method be used until 7 continuous days of active tablets have been completed.

Q: Влияют ли травяные чаи или добавки на действие Зоэли?

Official regulatory warnings highlight that the herbal remedy St John's Wort is known to cause reduced contraceptive effectiveness. This is due to its effect on the liver enzymes that clear the contraceptive hormones.

Q: Можно ли принимать Зоэли при грудном вскармливании?

According to the official product information, the medicine is not recommended for use while breastfeeding.

Q: Можно ли принимать Зоэли, если мне больше 35 лет?

Official warnings note that the risk of developing serious circulatory disorders (thrombosis) is known to further increase with age, especially in women over 35 years of age. This risk is particularly elevated in women who smoke.

Q: Влияет ли Зоэли на возможность забеременеть после прекращения приема?

Clinical data reported in the product information indicates that a rapid return to ovulation was observed in most women following the discontinuation of the medicine.

Q: Можно ли принимать Зоэли при наличии мигреней?

Migraine is listed as a common adverse reaction in the drug label. Additionally, the presence of migraine with aura is a known risk factor for stroke and is officially listed as a contraindication for all combined hormonal contraceptives.

Q: Как Зоэли может влиять на кожу (акне)?

Acne is officially listed as a Very Common adverse reaction, meaning it may occur in more than 1 in 10 women.

Q: Можно ли принимать Зоэли при наличии проблем со свертываемостью крови в семье?

Official contraindications state that a known hereditary or acquired predisposition to serious circulatory conditions (thrombosis) is an absolute contraindication for use. A positive family history of hypertriglyceridaemia (high fat levels in the blood) is also listed as a risk factor.

Q: Влияет ли курение на безопасность приема Зоэли?

Yes, official warnings strongly link smoking with an increased risk of developing serious circulatory disorders (such as thrombosis or stroke). This risk significantly increases with age, especially in women over 35 years old.

Q: Как часто нужно проходить обследование при приеме Зоэли?

Official product information suggests that a medical check-up be conducted at least once a year during use.

Q: Почему в упаковке Зоэли есть неактивные таблетки?

The yellow tablets are placebo (containing no active hormones). They are included in the 28-day pack to help the user maintain the daily habit of taking a tablet, ensuring continuity of the oral route of administration and adherence to the schedule.

Q: Можно ли пить алкоголь во время приема Зоэли?

The regulatory information indicates that alcohol is not expected to interact with the active components of the medicine.

Q: Может ли Зоэли помочь с сильными менструальными болями?

In addition to contraception, reported non-contraceptive health benefits indicate that menstrual pain may become less severe or may be reduced in some users.

Q: Правда ли, что Зоэли меньше влияет на либидо, чем другие таблетки?

The official product information lists decreased libido as an officially documented adverse reaction.

Q: Какие есть данные исследований о безопасности Зоэли?

Post-marketing surveillance includes extended prospective observational studies, such as the PRO-E2 safety study. These studies confirmed that the risk of venous thromboembolism (VTE) is considered to be at least as low as with combined oral contraceptives containing levonorgestrel.

Q: Можно ли принимать Зоэли во время путешествий?

If travelling across time zones, the primary concern is maintaining the correct daily timing of the active tablet. If the usual 24-hour window is exceeded, the user should refer to the full missed dose protocol outlined in the package leaflet.

Q: В чем особенность гормона номенгестрола, который содержится в Зоэли?

Nomegestrol acetate is a highly selective synthetic progestogen that is noted for its anti-androgenic properties. It has a relatively long elimination half-life (around 45 to 50 hours).

Q: Может ли Зоэли влиять на результаты анализов крови?

Official warnings state that combined hormonal contraceptives may influence the results of certain laboratory tests. This interference can affect parameters related to liver function, thyroid function, and coagulation.

Q: Почему у Зоэли другой гормональный режим по сравнению со стандартными КОК?

The 24-day active regimen followed by a short 4-day placebo period is an extended schedule. It is designed to ensure consistent ovarian suppression compared to standard 21-day active regimens.

Q: Какие есть предупреждения о Зоэли в официальных документах?

Key warnings include the risk of developing Venous Thromboembolism (VTE) or Arterial Thromboembolism (ATE). The VTE risk is officially noted as being highest during the first year of use or upon restarting after a break of four or more weeks.

Q: В каких странах Зоэли одобрен для использования?

The medicine has received Marketing Authorisation for use across the European Union (EU) Member States and the EEA-EFTA states, including Iceland, Liechtenstein, and Norway.

Q: Есть ли ограничения по возрасту для начала приема Зоэли?

Official regulatory documents state that the safety and efficacy of the medicine have not been established in post-menarcheal adolescents under 18 years of age.

Q: Может ли Зоэли вызывать межменструальные кровотечения?

The drug label indicates that changes to menstrual periods are a Very Common adverse reaction. These changes can include irregularity, as well as unscheduled bleeding or spotting (intermenstrual bleeding).

Q: Какие существуют исследования о долгосрочных эффектах Зоэли?

Post-marketing surveillance includes extended prospective observational studies which monitored the effects of sustained use over several years in large user cohorts. These studies help evaluate the long-term safety profile.

Q: Как правильно начать прием Зоэли, если до этого не использовалась контрацепция?

Official guidelines specify that tablet-taking generally starts on Day 1 of the cycle, corresponding to the first day of menstrual bleeding.

Q: Что делать, если появились очень сильные побочные эффекты от Зоэли?

Patient information advises that if potential signs of serious adverse reactions, such as thrombosis, myocardial infarction, or stroke, are noticed, the user is advised to seek emergency medical assistance.

Q: Меняется ли аппетит при приеме Зоэли?

The official product information lists both decreased appetite and appetite increase as documented adverse reactions in some users.

Q: Правда ли, что Зоэли имеет короткий период полувыведения?

The active progestogen component, nomegestrol acetate, has a relatively long elimination half-life of approximately 45 to 50 hours.

How to Store and Dispose of Zoely

The storage conditions for Zoely (nomegestrol acetate/estradiol) are strictly defined by regulatory documents to maintain the stability and quality of the tablets.

---

Storage Requirements

Condition	Requirement
Temperature	Store below 30 C (86 F).
Protection	Keep in a cool, dry place, protected from direct light and moisture.
Packaging	The tablets must remain in the original packaging (blister pack).
Child Safety	Store the medicine in a safe place, away from children.

---

Disposal Instructions

The medicine must not be used after the expiration date. Unused or expired Zoely, including missed tablets, must be discarded and handled as pharmaceutical waste. Disposal must follow local regulations to prevent environmental contamination.